CASSAVA SCIENCES INC

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

FLNA$0.45+0.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements Condensed Consolidated Balance Sheets – June 30, 2025 and December 31, 2024

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, In thousands, except share and par value data)

	June 30, 2025	December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$112,381	$128,574
Prepaid expenses and other current assets	2,440	7,958
Total current assets	114,821	136,532
Property and equipment, net	20,563	21,001
Total assets	$135,384	$157,533
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$42,822	$7,654
Accrued development expense	3,788	2,440
Accrued compensation and benefits	563	1,357
Other current liabilities	159	299
Total current liabilities	47,332	11,750
Other non-current liabilities	79	79
Total liabilities	47,411	11,829
Commitments and contingencies (Notes 8, 9 and 10)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	—	—
Common stock, $0.001 par value; 120,000,000 shares authorized; 48,307,896 and 48,203,179 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	48	48
Additional paid-in capital	560,663	550,767
Accumulated deficit	(472,738)	(405,111)
Total stockholders' equity	87,973	145,704
Total liabilities and stockholders' equity	$135,384	$157,533

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.